Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086695 · ClinicalTrials.gov registry record
Early Detection of Broken Hearts in Cancer Patients
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 43
- Enrollment target
NCT02086695: Completed study, sponsored by Mayo Clinic.
NCT02086695 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02086695 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
The early detection of BVZ or Sunitinib mediated cardiotoxicity using cardiac biomarkers and novel Transthoracic Echocardiogram (TTE) techniques may allow one to adjust treatment and/or administer prophylactic cardioprotective agents, prior to the development of irreversible cardiac dysfunction. We hypothesize that cardiac biomarkers, TVI/strain-derived indices will be able to accurately detect subtle cardiac injury at a time when conventional Left Ventricular Ejection Fraction (LVEF) remains normal in BVZ or Sunitinib mediated cardiotoxicity. Additionally, we hypothesize that Endothelial Function Test (EndoPAT) testing can detect early BVZ or Sunitinib mediated endothelial dysfunction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02086695
The ClinicalTrials.gov registry entry for NCT02086695 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02086695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02086695 about?
NCT02086695 is a clinical study titled "Early Detection of Broken Hearts in Cancer Patients". The early detection of BVZ or Sunitinib mediated cardiotoxicity using cardiac biomarkers and novel Transthoracic Echocardiogram (TTE) techniques may allow one to adjust treatment and/or administer prophylactic cardioprotective agents, prior to the development of irreversible cardiac dysfunction. We ...
What is the current status of trial NCT02086695?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2013-06. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT02086695?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.